Administration of the popular anti-inflammatory drug Celebrex (celecoxib, a nonsteroidal anti-inflammatory drug) in combination with Lipitor (atorvastatin, a cholesterol lowering drug or statin) halts the transition of early prostate cancer to its more aggressive and potentially deadly stage.
“Anti-androgen therapy slows the prostate cancer but eventually the cancer becomes androgen-independent, the therapy becomes ineffective and the cancer cells become more aggressive,” said Xi Zheng, assistant research professor at Rutgers, The State University of New Jersey, who conducted the study.
“Treatments available for the later stage cancers are not very good,” said Allan Conney, director of Rutgers’ Susan Lehman Cullman Laboratory for Cancer …read more

According to Wildon Farwell, M.D., of the Veterans Affairs Boston Healthcare System and colleagues, patients that are on cholesterol-lowering drugs – statins – may be at a lower risk for developing cancer — especially lung and colorectal cancers.
Statin users had a reduced risk of all cancer types compared with non-statin users. The incidence of cancer was 9.4 percent among statin users and 13.2 percent among non-statin users.
“Our findings support the hypothesis that statins may reduce the risk of cancer, in particular lung and colorectal cancers. This relationship may be affected by the [statin dose],” the authors write.
While it is not …read more